Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 41.28% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 10.06B.
Undervalued
The company’s latest PE is 50.94, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 316.11M shares, decreasing 0.85% quarter-over-quarter.
Held by Frank Sands
Star Investor Frank Sands holds 1.46M shares of this stock.